Who
Preetam Shah
Officer
Company insider
Files Form 4 as: Officer, Elicio Therapeutics; Chief Financial Officer, Cidara Therapeutics; EVP, CFO and Treasurer, Brainstorm Cell Therapeutics.
In numbers
- Trades disclosed
- 29
- Buys
- 2
- Sells
- 3
- Bought
- $77K
- Sold
- $35K
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 6 Sep 2019
- Last trade
- 16 Jul 2026
- Last filed
- 17 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Jul 2026filed 17 Jul 2026 | ELTX Elicio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,833 at $0.00 | filing |
| 16 Jul 2026filed 17 Jul 2026 | ELTX Elicio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,833 at $0.00 | filing |
| 2 Feb 2026filed 3 Feb 2026 | ELTX Elicio TherapeuticsBiotechnology | SEC FORM 4 Code A | —24,000 at $0.00 | filing |
| 2 Feb 2026filed 3 Feb 2026 | ELTX Elicio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —47,900 at $0.00 | filing |
| 2 Feb 2026filed 3 Feb 2026 | ELTX Elicio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —47,900 at $0.00 | filing |
| 2 Feb 2026filed 3 Feb 2026 | ELTX Elicio TherapeuticsBiotechnology | SEC FORM 4 Code A | —24,000 at $0.00 | filing |
| 15 Apr 2025filed 16 Apr 2025 | ELTX Elicio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —191,624 at $0.00 | filing |
| 30 Sep 2024filed 2 Oct 2024 | Cidara Therapeuticsoption or derivative | SEC FORM 4 Code A | —130,087 at $0.00 | filing |
| 15 Mar 2024filed 20 Mar 2024 | Cidara Therapeuticsoption or derivative | SEC FORM 4 Code A | —217,500 at $0.00 | filing |
| 15 Mar 2024filed 20 Mar 2024 | Cidara Therapeutics | SEC FORM 4 Code A | —108,750 at $0.00 | filing |
| 11 Mar 2024filed 12 Mar 2024 | Cidara Therapeutics | SEC FORM 4 Sold | $13K18,931 at $0.67 | filing |
| 27 Mar 2023filed 29 Mar 2023 | Cidara Therapeuticsoption or derivative | SEC FORM 4 Code A | —180,000 at $0.00 | filing |
| 27 Mar 2023filed 29 Mar 2023 | Cidara Therapeutics | SEC FORM 4 Code A | —90,000 at $0.00 | filing |
| 13 Mar 2023filed 13 Mar 2023 | Cidara Therapeutics | SEC FORM 4 Sold | $10K6,648 at $1.53 | filing |
| 19 Sep 2022filed 19 Sep 2022 | Cidara Therapeutics | SEC FORM 4 Sold | $12K15,642 at $0.77 | filing |
| 15 Sep 2022filed 19 Sep 2022 | Cidara Therapeuticsoption or derivative | SEC FORM 4 Code M | —50,000 at $0.00 | filing |
| 15 Sep 2022filed 19 Sep 2022 | Cidara Therapeutics | SEC FORM 4 Code M | —50,000 at $0.00 | filing |
| 31 Mar 2022filed 4 Apr 2022 | Cidara Therapeuticsoption or derivative | SEC FORM 4 Code A | —102,500 at $0.00 | filing |
| 31 Mar 2022filed 4 Apr 2022 | Cidara Therapeutics | SEC FORM 4 Code A | —51,250 at $0.00 | filing |
| 31 Mar 2022filed 4 Apr 2022 | Cidara Therapeutics | SEC FORM 4 Code A | —66,001 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.